Gilteritinib in combination with venetoclax, low‐dose cytarabine and actinomycin D for relapsed or refractory FLT3 ‐mutated acute myeloid leukaemia
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19318 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Andrius Zucenka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania. Hauptthemen laut MEDLINE: Cytarabine, Leukemia, Myeloid, Acute, Aniline Compounds, Pyrazines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
We have conducted a retrospective, single‐centre analysis of 20 patients with relapsed or refractory FLT3‐mutated acute myeloid leukaemia (FLT3m AML) who received a salvage quadruplet regimen consisting of gilteritinib, venetoclax, low‐dose cytarabine and actinomycin D (G‐ACTIVE). G‐ACTIVE resulted in a 95% (19/20) overall response rate and 75% (15/20) complete remission and complete remission with an incomplete platelet recovery (CR + CRp) rate. Out of 13 transplant‐eligible patients, 11 (86%) proceeded to an allogeneic stem cell transplantation. The median overall survival and relapse‐free survival after G‐ACTIVE were 32 and 12.9 months respectively. The Day 60 mortality rate was 15%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.
- Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
ORCID-Profile: Andrius Zucenka
Zitieren
APA
Zucenka, A., & Griskevicius, L. (2024). Gilteritinib in combination with venetoclax, low‐dose cytarabine and actinomycin D for relapsed or refractory FLT3 ‐mutated acute myeloid leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.19318
Vancouver
Zucenka A, Griskevicius L. Gilteritinib in combination with venetoclax, low‐dose cytarabine and actinomycin D for relapsed or refractory FLT3 ‐mutated acute myeloid leukaemia. British Journal of Haematology. 2024. doi:10.1111/bjh.19318
BibTeX
@article{Zucenka2024,
author = {Zucenka, Andrius and Griskevicius, Laimonas},
title = {Gilteritinib in combination with venetoclax, low‐dose cytarabine and actinomycin D for relapsed or refractory FLT3 ‐mutated acute myeloid leukaemia},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19318}
}
EUVIMED